Titlebook: Drug Resistance in Leukemia and Lymphoma III; G. J. L. Kaspers,R. Pieters,A. J. P. Veerman Book 1999 The Editor(s) (if applicable) and The

松果

epidermis

Homocystinuria

Preliminary Immunocytochemical Studies of MDR-1 and MDR-3 Pgp Expression in B-Cell Leukaemias5a patient which is the first report of MDR-3 Pgp expression being detected in AML; suggesting that MDR-3 Pgp expression may be limited to particular subtypes of this disease..Results from B-NHL cases were inconclusive with varying expression of MDR-1 and MDR-3 Pgps observed. Work is currently under

騷動

A Mutation in the Promoter of the Multidrug Resistance Gene (,) in Human Hematological Malignancies Sequence analysis revealed that all patients were heterozygous for a point mutation in the promoter (T-C transition at +8). Four normals (4%) were found to be heterozygous for the mutation. Confirmation of the mutation was performed by oligonucleotide probe hybridization. All but two of the AML pat

AVERT

Reproducible Flow Cytometric Methodology for Measuring Multidrug Resistance in Leukaemic Blasts47 (57%) samples had both low dnr accumulation and at least one positive confirmatory test (a modulated functional assay and/or protein overexpression) and were categorised as “confirmed MDR”. 15/47 patients (32%) were MDR negative in all 4 assays. 5/47 (11%) patients had unconfirmed low dnr accumul

padding

減弱不好

The Lung Resistance Protein (LRP) Predicts Poor Outcome in Acute Myeloid Leukemianegative patients but only 8 months for LRP-positive patients (p = 0.006). Disease-free survival was 9 months for LRP-negative patients and 6 months for LRP-positive patients (p = 0.078). Thus LRP predicts for poor outcome indicating that the LRP gene is a clinically relevant drug resistance gene in

繼而發(fā)生

MRP Expression in Acute Myeloid Leukemia to patients with low MRP expression. MRP does not predict for response to induction chemotherapy but intermediate or high MRP expression might be associated with shorter overall survival of the patients.

憤慨點吧